id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9020 R30721 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Death (Mean follow up 3-4 years) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.76 [0.57;5.49] C | 3/621 4,695/1,710,441 | 4,698 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8983 R30486 |
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 | Infant death (0–364 days of age) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
4.57 [0.18;118.16] C excluded (control group) |
0/13 1/173 | 1 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8984 R30498 |
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 | Infant death (0–364 days of age) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
14.01 [0.83;236.71] C excluded (control group) |
0/13 2,048/719,509 | 2,048 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8985 R30510 |
Artama (Levetiracetam) (Controls unexposed, sick), 2013 | Infant death (0–364 days of age) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 13.00 [0.68;247.90] C | 0/13 5/1,793 | 5 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 2.96 [0.53;16.41] | 4,703 | 634 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed, NOS; 2: Levetiracetam) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 8983, 8984